PAREXEL Enters Alliance with ASAN Medical Center

PAREXEL International Corp., a leading global biopharmaceutical services provider, announced yesterday that it has entered into an agreement with Seoul-based ASAN Medical Center (AMC) for clinical development services market in Asia.

The alliance offers regional and international sponsors with access to quality clinical trial services throughout Asia, with a focus on early phase development.

"Through our collaboration with AMC we look forward to helping our clients take advantage of opportunities to support their Korea-based development and commercialization programs to benefit patients in Korea, throughout Asia, and around the world," said Mark A. Goldberg, M.D., chief operating officer, PAREXEL International.

"PAREXEL provides clients with patient access in key therapeutic areas for early phase development through our early phase units and global alliance network. Our relationship with the AMC affords us the opportunity to further extend this capability into Asia. With AMC’s leadership in clinical trials, in-depth expertise, state-of-the art facilities, and a renowned network of hospitals, we believe our alliance will offer unique advantages to the Korean biopharmaceutical industry."